Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Post-ASH 2022 MPN Highlights

17 January 2023 | Virtual Meeting

Post-ASH 2022 MPN Highlights

17 January 2023 | Virtual Meeting

Expert-led presentations & discussions on key abstracts in MPNs from ASH 2022

The Post-ASH 2022 MPN Highlights virtual workshop took place on 17 January 2023, and featured a series of short presentations on selected abstracts in myeloproliferative neoplasms from the 64th ASH Annual Meeting presented by experts with interactive panel discussions after each session.

Combination and Emerging Targeted Therapies in Myelofibrosis Plenary review PV, ET low risk MF same drugs new data new endpoints? Atypical MPN Mastocytosis

Session 1: Combination and Emerging Targeted Therapies in Myelofibrosis

Jean-Jacques Kiladjian
Ruxolitinib and pegylated IFN alfa-2a in patients with myelofibrosis
Jean-Jacques Kiladjian Saint-Louis Hospital & Paris Diderot University, Paris, France
Abdulraheem Yacoub
Efficacy and safety of add-on parsaclisib to ruxolitinib therapy in myelofibrosis
Abdulraheem Yacoub University of Kansas Medical Center, Kansas City, KS, United States
Francesco Passamonti
Navitoclax and ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis
Francesco Passamonti University of Insubria, Varese, Italy
John Mascarenhas
Pelabresib with ruxolitinib for JAK inhibitor treatment-naïve patients
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Panel discussion
Raajit Rampal
TP-3654 in pts previously treated with/ineligible for JAK inhibitor therapy
Raajit Rampal Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Vikas Gupta
Primary Analysis of the FREEDOM Trial
Vikas Gupta Princess Margaret Cancer Centre, Toronto, Canada
Aaron Gerds
Updated Results from the Momentum Phase III Study
Aaron Gerds Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States
Stephen Oh
Pacritinib is a potent ACVR1 Inhibitor in patients with MF
Stephen Oh Washington University in St. Louis, St. Louis, MO, United States
Panel discussion

Session 2: Plenary review

Bethan Psaila
Review of plenary presentation 6, discovery of INCA033989
Bethan Psaila University of Oxford, Oxford, United Kingdom
Panel discussion
794257347

Session 3: PV, ET low risk MF same drugs new data new endpoints? Atypical MPN Mastocytosis

Claire Harrison
Ruxolitinib vs best available therapy for PV
Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Harinder Gill
Bomedemstat (IMG-7289) for treating ET
Harinder Gill University of Hong Kong, Hong Kong
Stephen Oh
Bone marrow fibrosis changes do not correlate with efficacy outcomes in MF
Stephen Oh Washington University in St. Louis, St. Louis, MO, United States
Panel discussion
Deepti Radia
Avapritinib in patients with advanced systemic mastocytosis
Deepti Radia Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Srdan Verstovsek
Results from the FIGHT-203 study of pemigatinib
Srdan Verstovsek The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion

The continued success of the post-ASH meetings is in no small part due to the ongoing funding of supporters, allowing unique opportunities for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes.
For more information about supporting future meetings and activities, please contact us here.

For the latest updates in myeloproliferative neoplasms, visit The MPN Channel

The content of VJHemOnc is intended for healthcare professionals